In 2012, the multikinase inhibitor ponatinib (Iclusig®, Figure 2) received FDA approval as the third-generation ABL inhibitor for the treatment of patients with CML and Ph + ALL.12 Here, ABL1 is linked to acute lymphoblastic leukemia.